Skip to main content
Erschienen in: BMC Nephrology 1/2019

Open Access 01.12.2019 | Research article

Impact of Pneumocystis jirovecii pneumonia on kidney transplant outcome

verfasst von: Ji Eun Kim, Ahram Han, Hajeong Lee, Jongwon Ha, Yon Su Kim, Seung Seok Han

Erschienen in: BMC Nephrology | Ausgabe 1/2019

Abstract

Backgrounds

Pneumocystis jirovecii pneumonia (PCP) remains an important cause of morbidity and mortality in kidney transplant recipients. While the acute phase toxicity in patients with PCP is well-characterized, there is a lack of data on the effects of PCP on long-term graft outcome.

Method

This retrospective observational study analyzed 1502 adult patients who underwent kidney transplantation at Seoul National University Hospital between 2000 and 2017. After a propensity score matching was performed, the graft and survival outcomes were compared between PCP-negative and PCP-positive groups.

Results

A total of 68 patients (4.5%) developed PCP after transplantation. The multivariable Cox analysis showed that positivity for cytomegalovirus and lack of initial oral antibiotic prophylaxis were risk factors of post-transplant PCP. The PCP-positive group had higher hazard ratios of graft failure [adjusted hazard ratio (HR), 3.1 (1.14–8.26); P = 0.027] and mortality [adjusted HR, 11.0 (3.68–32.80); P < 0.001] than the PCP-negative group. However, the PCP event was not related with subsequent development of de novo donor-specific antibodies or pathologic findings, such as T-cell or antibody mediated rejection and interstitial fibrosis and tubular atrophy.

Conclusions

PCP is a risk factor of long-term graft failure and mortality, irrespective of rejection. Accordingly, appropriate prophylaxis and treatment is needed to avoid adverse transplant outcomes of PCP.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12882-019-1407-x) contains supplementary material, which is available to authorized users.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CI
Confidence interval
CKD
Chronic kidney disease
CMV
Cytomegalovirus
DMN
Diabetic nephropathy
DSA
Donor-specific antibody
HLA
Human leukocyte antigen
HR
Hazard ratio
PCP
Pneumocystis jirovecii pneumonia

Background

With the continued development of immunosuppressive regimens in the past decade, death-censored graft failures have gradually decreased in recipients of both living and deceased kidney recipients [1, 2]. However, the mortality rates in patients with functioning grafts remain unchanged over the past 10 years [1, 2]. More information on the causes of mortality unrelated to graft failure is therefore needed to further improve the survival of transplant recipients.
Infection is an important factor in relation to the risk of death in kidney transplant recipients, and the second most common cause of death after cardiovascular disease in patients with functioning grafts [35]. The incidence of most infectious diseases, such as urinary tract infection and sepsis, has been steadily maintained over the past 15 years [6]. Despite its clinical implication of these infectious diseases, there is little data on immunologic outcomes after specific infectious disease in transplant recipients. Further studies of post-transplant infectious events are therefore needed to characterize and ultimately improve survival outcomes.
Pneumocystis jirovecii is an opportunistic pathogen that causes severe pulmonary infection in immunocompromized hosts [7]. The incidence of P. jirovecii pneumonia (PCP) varies from 0.6 to 14% among kidney transplant recipients without prophylaxis, with a mortality of up to 50% despite aggressive antibiotic therapy [8, 9]. Several studies have investigated the relationship between PCP and mortality [9, 10], but the effect of PCP on graft rejection and overall graft outcomes has been less-well explored. Certain infections such as cytomegalovirus (CMV) and BK virus have demonstrated relationships with acute rejection during the early posttransplant period [1114]. This is a meaningful clinical issue, given that appropriate infection prophylaxis and treatment regimens could be implemented to address subsequent immunological complications. However, the clinical implications of PCP have not yet been resolved. Herein, we evaluated the impact of PCP on kidney transplant outcomes, including graft failure and rejection.

Methods

Study design and subjects

The study design was approved by the institutional review board of Seoul National University Hospital (no. H-1805-173-948) and complied with the Declaration of Helsinki. This retrospective observational study included total 1827 patients who had kidney transplantation at Seoul National University Hospital from January 2000 to December 2017. Patients who were under 18 years old (n = 260) or who received simultaneous kidney–pancreas or kidney–liver transplants (n = 65) were excluded. Consequently, the remaining 1502 patients were finally included and their data were reviewed. The requirement of informed consent was waived by the board.

Data collection and definitions

Data from the kidney transplant recipients were collected from the electronic medical records. Demographic characteristics including age, gender, height, weight, and body mass index were collected. Pre-transplant status, including prior history of transplantation, the type and duration of dialysis, history of diabetic nephropathy as a cause of kidney failure, and comorbidities such as hypertension and diabetes, was evaluated.
Results for both recipient and donor ABO blood groups (ABO) and human leukocyte antigen (HLA) typing were collected to evaluate ABO compatibility and the number of HLA mismatches. Immunosuppressive therapy was determined, including induction therapy with basiliximab or anti-thymocyte globulin, and calcineurin inhibitors for maintenance therapy. A combination of steroids, mycophenolic acid, and calcineurin inhibitors was the standard maintenance immunosuppressive regimen in our center. PCP was defined as the presence of findings suspicious of PCP detected by a radiologist on chest computed tomography combined with PCP positivity on polymerase chain reaction or direct immunofluorescence stain of sputum or bronchoalveolar lavage fluid. Initial use of oral prophylactic antibiotics was defined as a prescription of trimethoprim/sulfamethoxazole for more than 4 weeks during the first month after kidney transplantation. There were no cases with pentamidin or atovaquon for prophylaxis. CMV positivity was defined as > 20 copies/ml on polymerase chain reaction or positive result on viral culture, according to the definition of CMV infection [15].

Transplant outcomes

The primary outcome was death-censored graft failure defined as a return to dialysis or kidney re-transplantation. The secondary outcome was all-cause mortality, based on data obtained from the National Database of Statistics Korea. All patients were followed until graft failure or March 2018. Data on biopsy-proven acute T-cell-mediated rejection, acute antibody-mediated rejection, and interstitial fibrosis and tubular atrophy were also collected. Protocol biopsies were performed at zero-time (postreperfusion), on the 10th day and 1 year after transplantation, and every year thereafter. Additional kidney biopsies were performed if graft function deteriorated or any suspicious symptoms or signs of rejection were observed. All pathologic findings were examined by a nephropathologist. The development of de novo donor-specific antibody (DSA) was defined as any newly developed anti-HLA class I or II antibody.

Statistical analysis

All statistical analyses were performed using Stata software (version 15.1, StataCorp, College Station, TX, USA). Data are expressed as mean ± standard deviation for continuous variables or counts with percentages for categorical variables. Among the baseline characteristics, categorical variables were compared using χ2 and Fisher’s exact tests and continuous variables were compared using Student’s t-test. Risk factors for PCP occurrence were analyzed using univariable and multivariable Cox proportional hazard models.
Propensity score matching was performed to account for the imbalance in baseline characteristics between the PCP-positive and -negative groups. Scores were created with matching variables including age, gender, donor type, type of pre-transplant dialysis, hypertension, the usage of prophylactic antibiotics, and CMV positivity which had P values under 0.1 in multivariable Cox analysis for the risk of PCP. Then, the cases were matched on propensity score in a 1:2 block, using a nearest neighbor matching algorithm with replacement, using the statistical package psmatch2. Following propensity score matching, graft survival, overall patient survival, risk of rejection and development of DSA were analyzed using univariable and multivariable Cox proportional hazard models. Because PCP infection was a time-dependent covariant in the Cox model, we used the stssplit function in Stata to split the time at which PCP occurred. The proportionality assumption was checked for proportional hazard Cox regression. Survival curves were drawn using the Kaplan–Meier method, with comparisons between groups carried out using the log-rank test. A P value < 0.05 was considered to indicate statistical significance.

Results

Baseline characteristics and risk factor of PCP

Table 1 shows the demographic and clinical characteristics of the total study subjects, according to the PCP status. The median duration of follow-up was 6.2 years (interquartile range, 3.0–9.6 years; maximum 18.3 years). Of the 1502 patients, 68 (4.5%) experienced PCP after kidney transplantation, with an infection rate of 6.8 cases per 1000 person-years. The median time to the development of PCP was 5.2 months (interquartile range, 3.9–10.0 months), and 79.4% of cases developed during the first year after transplantation. There were significant differences between PCP-positive and -negative patients with respect to gender, type of pre-transplant dialysis, ABO-incompatibility, desensitization therapy, induction regimen, hypertension and CMV positivity. After adjustment for multiple covariates, CMV positivity and the non-use of oral prophylactic antibiotics were associated with an increased risk of PCP (Table 2).
Table 1
Baseline characteristics of total study subjects
Variables
Total
(n = 1502)
PCP negative
(n = 1434)
PCP positive
(n = 68)
P
Age (years)
45.3 ± 13.0
45.1 ± 13.0
48.3 ± 14.4
0.053
Female (%)
39.1
39.9
23.5
0.007
Body mass index (kg/m2)
22.5 ± 3.7
22.5 ± 3.8
22.6 ± 2.6
0.969
Donor type (%)
   
0.124
 Living
67.4
67.8
58.8
 
 Deceased
32.6
32.2
41.2
0.391
  Standard criteria donor
25.4
25.2
29.4
 
  Expanded criteria donor
7.2
7.0
11.8
 
Pre-transplant dialysis (%)
   
0.005
 Preemptive
15.6
15.3
22.1
 
 Hemodialysis
65.2
66.0
47.1
 
 Peritoneal dialysis
19.2
18.7
30.9
 
Duration of dialysis (months)
40.1 ± 47.7
40.0 ± 47.5
42.9 ± 51.9
0.650
Re-transplantation
7.2
7.2
7.4
0.958
ABO-incompatible (%)
7.4
6.8
19.1
<  0.001
HLA mismatch (numbers)
3.1 ± 1.7
3.1 ± 1.7
3.1 ± 1.7
0.983
 HLA-A
0.9 ± 0.7
0.9 ± 0.7
1.0 ± 0.8
0.344
 HLA-B
1.2 ± 0.7
1.2 ± 0.7
1.2 ± 0.8
0.861
 HLA-DR
1.0 ± 0.7
1.0 ± 0.7
0.9 ± 0.7
0.291
Calcineurin inhibitor (%)
   
0.260
 None
3.1
3.0
5.9
 
 Cyclosporine
13.0
13.2
8.8
 
 Tacrolimus
83.9
83.8
85.3
 
mTOR inhibitor (%)
1.9
1.9
2.9
0.535
Induction regimen (%)
   
0.022
 None
19.0
19.6
7.4
 
 Basliximab
79.6
78.9
92.6
 
 Antithymocyte globulin
1.4
1.5
0
 
Desensitization (%)
11.5
10.9
22.1
0.005
Diabetes mellitus (%)
19.0
18.9
22.1
0.517
Hypertension (%)
89.9
89.5
98.5
0.016
DMN for kidney failure (%)
16.4
16.3
19.1
0.543
Positivity for CMV (%)
21.4
19.5
60.3
<  0.001
Oral prophylactic antibiotics (%)
18.8
19.2
10.3
0.067
Comparisons were evaluated between PCP-negative and PCP-positive groups
Abbreviations: PCP Pneumocystis jirovecii pneumonia, HLA human leukocyte antigen, DMN diabetic nephropathy, mTOR mammalian target of rapamycin, CMV cytomegalovirus
Table 2
Risk factors for PCP occurrence after kidney transplantation
Variables
Univariable
Multivariable*
HR (95% CI)
P
HR (95% CI)
P
Age
1.02 (1.00–1.04)
0.015
stratified
 
Female
0.46 (0.27–0.81)
0.007
0.56 (0.30–1.06)
0.074
Body mass index
1.01 (0.95–1.08)
0.761
  
Donor type
 Living donor
1 (reference)
 
1 (reference)
 
 Standard criteria donor
1.43 (0.83–2.46)
0.194
1.89 (0.91–3.94)
0.090
 Expanded criteria donor
2.22 (1.03–4.77)
0.041
1.14 (0.37–3.50)
0.818
Pre-transplant dialysis
 Preemptive
1 (reference)
 
1 (reference)
 
 Hemodialysis
0.51 (0.28–0.95)
0.033
0.42 (0.19–0.89)
0.023
 Peritoneal dialysis
1.10 (0.57–2.13)
0.786
0.91 (0.39–2.11)
0.829
Duration of dialysis
1.00 (1.00–1.01)
0.464
  
Re-transplantation
1.03 (0.41–2.56)
0.948
  
ABO-incompatible
3.75 (2.13–6.93)
<  0.001
1.60 (0.38–6.77)
0.521
HLA mismatch (numbers)
1.02 (0.88–1.17)
0.834
  
Calcineurin inhibitor
 None
1 (reference)
 
1 (reference)
 
 Cyclosporine
0.27 (0.08–0.97)
0.045
0.34 (0.07–1.65)
0.179
 Tacrolimus
0.52 (0.19–1.42)
0.202
0.41 (0.11–1.54)
0.185
Induction regimen
  
Stratified
 
 None
1 (reference)
   
 Basiliximab
4.43 (1.73–11.32)
0.002
  
 Antithymocyte globulin
NE
NE
  
Desensitization
2.67 (1.49–4.76)
0.001
2.67 (0.66–10.76)
0.167
Diabetes mellitus
1.31 (0.74–2.33)
0.354
  
Hypertension
7.87 (1.09–56.73)
0.041
6.59 (0.80–54.14)
0.080
DMN for kidney failure
1.32 (0.72–2.41)
0.373
  
Positivity of CMV
6.41 (3.93–10.44)
<  0.001
4.48 (2.58–7.79)
< 0.001
Oral prophylactic antibiotics
0.54 (0.25–1.19)
0.129
0.35 (0.15–0.82)
0.016
*Adjusted for gender, donor type, ABO compatibility, desensitization, hypertension, positivity of CMV and oral prophylactic antibiotics. Because age and induction regimen violated the proportionality assumption, multivariable Cox model was stratified by age and induction regimen
Abbreviations: PCP Pneumocystis jirovecii pneumonia, HR hazard ratio, CI confidence interval, HLA human leukocyte antigen, NE not estimable, DMN diabetic nephropathy, CMV cytomegalovirus

PCP and transplant outcomes

We performed propensity score matching to mitigate the difference in baseline characteristics between the PCP-positive and -negative groups. Table 3 shows the baseline characteristics of the two groups of patients after propensity score matching. Among 68 PCP-positive recipients, 9 (13.2%) patients developed death-censored graft failure. Figure 1 shows the Kaplan-Meier curves for death-censored graft survival, and the curves were separated by the presence of PCP (P = 0.008). Cox regression analysis considering PCP as a time-dependent variable was subsequently performed. Both univariable and multivariable analyses showed a significant relationship between PCP and graft failure, with HRs of 3.34 (1.31–8.56) (P = 0.012) and 3.33 (1.30–8.53) (P = 0.012), respectively. Although the acute T cell-mediated and antibody-mediated rejection episodes or other immunological findings such as interstitial fibrosis and tubular atrophy and de novo DSA were additionally adjusted, the PCP-positive recipients had a higher risk of death-censored graft failure than the PCP-negative recipients (adjusted HR, 3.06 [1.14–8.26]); P = 0.027).
Table 3
Baseline characteristics after propensity score matching
Variables
PCP negative
(n = 118)
PCP positive
(n = 68)
P
Age (years)
46.7 ± 14.6
48.3 ± 14.4
0.504
Female (%)
21.8
23.5
0.792
Body mass index (kg/m2)
22.5 ± 3.4
22.6 ± 2.6
0.509
Donor type (%)
  
0.447
 Living
64.5
58.8
 
 Deceased
35.5
41.2
0.846
  Standard criteria donor
24.5
29.4
 
  Expanded criteria donor
10.9
11.8
 
Pre-transplant dialysis (%)
  
0.102
 Preemptive
15.3
22.1
 
 Hemodialysis
68.6
47.1
 
 Peritoneal dialysis
16.1
30.9
 
Duration of dialysis (months)
47.4 ± 52.1
44.1 ± 54.0
0.704
Re-transplantation
6.8
7.4
0.883
ABO-incompatible (%)
7.6
19.1
0.019
HLA mismatch (numbers)
3.1 ± 1.5
3.1 ± 1.7
0.915
Calcineurin inhibitor (%)
  
0.349
 None
2.5
5.9
 
 Cyclosporine
13.6
8.8
 
 Tacrolimus
83.9
85.3
 
Induction regimen (%)
  
0.108
 None
15.3
7.4
 
 Basliximab
82.2
92.6
 
 Antithymocyte globulin
2.5
0
 
Desensitization (%)
11.0
22.1
0.043
Diabetes mellitus (%)
20.3
22.1
0.781
Hypertension (%)
94.1
98.5
0.149
DMN for kidney failure (%)
19.5
19.1
0.950
Positivity for CMV (%)
57.6
60.3
0.722
Oral prophylactic antibiotics (%)
14.4
10.3
0.420
Acute T cell-mediated rejection (%)
66.9
61.8
0.475
Acute antibody-mediated rejection (%)
9.3
11.8
0.596
Interstitial fibrosis and tubular atrophy (%)
37.3
42.6
0.471
De novo donor-specific antibody (%)
12.7
11.8
0.850
Comparisons were evaluated between PCP-negative and PCP-positive groups
Abbreviations: PCP Pneumocystis jirovecii pneumonia, HLA human leukocyte antigen, DMN diabetic nephropathy, CMV cytomegalovirus
The clinical information on the PCP-positive patients with graft failure (n = 9) are shown in Additional file 1: Table S1. All the patients were male and had no history of prophylactic antibiotics usage after transplantation. During the admission period, 8 of 9 patients (88.9%) experienced acute kidney injury according to the Kidney Disease Improving Global Outcomes criteria [16], and 4 of them (50%) did not have recovered their graft functions at discharge despite the recovery from PCP. To determine the cause of the elevated risk of graft failure, we evaluated the effect of PCP on the risk of subsequent occurrence of rejection, interstitial fibrosis and tubular atrophy, and de novo DSAs. However, these outcomes did not differ between PCP-positive and –negative groups (Table 4). The results suggest that different graft failure rates might not be attributable to the conventional immunological transplant episodes, but might be related with non-immunological factors such as concurrent acute kidney injury.
Table 4
Risk of rejection and development of de novo donor-specific antibody according to the occurrence of PCP
Outcomes
Univariable
Multivariable*
HR (95% CI)
P
HR (95% CI)
P
T-cell mediated rejection
0.49 (0.19–1.26)
0.140
0.50 (0.19–1.28)
0.148
Antibody mediated rejection
0.70 (0.15–3.27)
0.651
0.66 (0.14–3.08)
0.597
Interstitial fibrosis and tubular atrophy
1.51 (0.72–3.15)
0.274
1.62 (0.77–3.41)
0.204
De novo donor specific antibody
0.87 (0.28–2.66)
0.801
0.88 (0.29–2.70)
0.821
*Adjusted for variables which had P values less than 0.1 in Table 3
Abbreviations: HR hazard ratio, CI confidence interval
During the follow-up period, 11 patients (16.2%) and 13 patients (11.0%) died in the PCP-positive and -negative groups, respectively. The 28 PCP-positive patients had concurrent other infectious diseases, and 8 patients died (28.6%). All-cause mortality was higher in the PCP-positive group than in the PCP-negative group (Fig. 2). The PCP-positive group had a higher risk of mortality [adjusted HR, 10.99 (3.68–32.80); P < 0.001] than the PCP-negative group.
Additional file 1 Table S2 lists the PCP-positive patients who died. Nine of Eleven patients (81.8%) died within 3 months after the occurrence of PCP. The most common cause of death was acute respiratory distress syndrome related with PCP.

Discussion

Pneumocystis jirovecii is an ascomycetous fungus that causes opportunistic infections, and its life cycle remains unknown because it cannot be consistently cultured [17, 18]. Furthermore, the epidemiology of human PCP is unclear yet [17, 19]. Due to little knowledge about Pneumocystis jirovecii, it is necessary to investigate whether the long term effect of PCP on allografts is due to the infection alone or with chronic inflammatory process and other unknown mechanisms. Although PCP is relatively common after kidney transplantation, its clinical implications, especially in relation to graft outcomes, have not been fully evaluated. The results of the present study demonstrated that male gender and CMV positivity were risk factors associated with PCP, and the use of oral prophylactic antibiotics seemed to prevent the risk of PCP. The occurrence of PCP increased the risk of long-term graft failure; however, this relationship was not dependent of rejection, interstitial fibrosis and tubular atrophy, or de novo DSAs. Because PCP was associated with both graft failure and overall mortality, intensive treatment and prophylaxis is recommended after transplantation.
Previous studies have shown that CMV infection increases a risk of PCP [2022], as supported by the present results. This may be because CMV might modify the host immune response, leading to immune suppression [23, 24]. CMV infection affects the T cell compartment and accelerates aging of T cells [25]. T-cells, especially CD4 T cells, are important factors affecting the vulnerability to and resolution of PCP [26], and alteration of the T cell response by CMV might aggravate pulmonary impairment during PCP activation [27].
Pre-transplant dialysis was newly identified as a protective factor of PCP. None of previous studies have included this factor in the analysis models. Uremic condition is linked to altered immunological responses [28]. Accordingly, appropriate pre-transplant resolution of uremia would decrease the risk of post-transplant PCP. However, a long-term pre-transplant dialysis negatively affects the host immune status [29]. Additionally, other detailed information such as the dose or adequacy of dialysis which the present study did not obtain could function as an interacting factor. Further studies are needed to determine the underlying mechanisms of above relationship.
The occurrence of PCP itself did not affect the risk of following development of acute rejection and de novo DSA production. Nevertheless, occurrence of PCP was significantly associated with overall graft failure. As has been previously demonstrated, viral infections such as CMV, BK virus, and hepatitis C virus, and certain bacterial infections such as Pseudomonas aeruginosa, affect allograft dysfunction by modulating non-immunological factors such as hemodynamic change in addition to immunological factors [30, 31]. In our results, PCP did not increase the risk of any rejection after infection, suggesting that non-immunological factors may be the cause underlying the observations. Certain PCP-positive patients had concurrent acute kidney injury and half of them did not achieve the recovery from this condition, which might leave the grafts with non-immunological damages. However, through non-immunological pathways, infections may also induce allograft injury by stimulating the production of proinflammatory cytokines such as interleukin-1, interleukin-6, and interleukin-8 [32]. These proinflammatory cytokines are known to be upregulated in patients with PCP [26].
Mortality risk was elevated in patients with PCP. Nine out of eleven (81.8%) patients died within 3 months after diagnosis of PCP infection. The causes of death in these patients were either PCP itself or the other infection superimposed on PCP. Thus, considering both the significant effect of PCP on mortality and the negative effect on graft outcome over long-term period, prophylaxis against PCP may be strongly recommended. According to the Kidney Disease Improving Global Outcomes guideline, it is recommended that all recipients receive prophylaxis against PCP for 3–6 months after transplantation [33]. However, definitive guidelines on the duration and dosage of PCP prophylaxis are not available and more research is needed to determine the appropriate approach [33].
Although our data are informative, there are some limitations. First, it was a retrospective study, making it difficult to demonstrate cause and effect definitively. Nevertheless, the study achieved its primary purpose by demonstrating the relationship between PCP and transplant outcomes. Second, the current definition of prophylactic antibiotics was 1 month, which was shorter than the guideline recommendation (i.e., 3–6 months), which might increase overall risk of PCP in study subjects. The duration of antibiotic prophylaxis (i.e., more than 4 weeks) might differ between centers, which could also alter the risk of PCP or other transplant outcomes. However, this did not hinder the study purpose on the relationship between PCP and transplant outcomes. Lastly, the present observational study design could not determine the mechanisms underlying the risk and subsequent effect of PCP.

Conclusion

Risk of PCP is aggravated in the kidney transplant cases with male gender, positivity for CMV, and non-use of oral prophylactic antibiotics. PCP significantly increases both the risks of mortality and graft failure. Accordingly, robust prophylaxis may be needed to prevent PCP and subsequent graft failure. The present results will be the basis of the future clinical trials on the use of prophylaxis in kidney transplant recipients.

Acknowledgements

Not applicable.
The study design was approved by the institutional review board of Seoul National University Hospital (no. H-1805-173-948) and the requirement of informed consent was waived by the board.
Not Applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Hart A, Smith JM, Skeans MA, Gustafson SK, Stewart DE, Cherikh WS, et al. OPTN/SRTR 2015 annual data report: kidney. Am J Transplant. 2017;17(Suppl 1):21–116.CrossRef Hart A, Smith JM, Skeans MA, Gustafson SK, Stewart DE, Cherikh WS, et al. OPTN/SRTR 2015 annual data report: kidney. Am J Transplant. 2017;17(Suppl 1):21–116.CrossRef
2.
Zurück zum Zitat Freitas MC. Kidney transplantation in the US: an analysis of the OPTN/UNOS registry. Clin Transpl. 2011:1–16. Freitas MC. Kidney transplantation in the US: an analysis of the OPTN/UNOS registry. Clin Transpl. 2011:1–16.
3.
Zurück zum Zitat Evenepoel P, Vanrenterghem Y. Death with functioning graft--a preventable cause of graft loss. Ann Transplant. 2001;6(4):17–20.PubMed Evenepoel P, Vanrenterghem Y. Death with functioning graft--a preventable cause of graft loss. Ann Transplant. 2001;6(4):17–20.PubMed
4.
Zurück zum Zitat de Castro Rodrigues Ferreira F, Cristelli MP, Paula MI, Proenca H, Felipe CR, Tedesco-Silva H, et al. Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center. J Nephrol. 2017;30(4):601–6.CrossRef de Castro Rodrigues Ferreira F, Cristelli MP, Paula MI, Proenca H, Felipe CR, Tedesco-Silva H, et al. Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center. J Nephrol. 2017;30(4):601–6.CrossRef
5.
Zurück zum Zitat Kahwaji J, Bunnapradist S, Hsu JW, Idroos ML, Dudek R. Cause of death with graft function among renal transplant recipients in an integrated healthcare system. Transplantation. 2011;91(2):225–30.CrossRef Kahwaji J, Bunnapradist S, Hsu JW, Idroos ML, Dudek R. Cause of death with graft function among renal transplant recipients in an integrated healthcare system. Transplantation. 2011;91(2):225–30.CrossRef
6.
Zurück zum Zitat Bae SDC, Kucirka L, DiBrito S, Avery R, Garonzik J, Segev D. Trends in infection among kidney transplant recipients, 1999–2013. Am J Transplant. 2017;17(suppl 3):9–50. Bae SDC, Kucirka L, DiBrito S, Avery R, Garonzik J, Segev D. Trends in infection among kidney transplant recipients, 1999–2013. Am J Transplant. 2017;17(suppl 3):9–50.
7.
Zurück zum Zitat Brakemeier S, Pfau A, Zukunft B, Budde K, Nickel P. Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation. Pharmacol Res. 2018;134:61–7.CrossRef Brakemeier S, Pfau A, Zukunft B, Budde K, Nickel P. Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation. Pharmacol Res. 2018;134:61–7.CrossRef
8.
Zurück zum Zitat Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770–82 table of contents.CrossRef Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770–82 table of contents.CrossRef
9.
Zurück zum Zitat Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009;88(1):135–41.CrossRef Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009;88(1):135–41.CrossRef
10.
Zurück zum Zitat Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest. 2005;128(2):573–9.CrossRef Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest. 2005;128(2):573–9.CrossRef
11.
Zurück zum Zitat Kaminski H, Fishman JA. The cell biology of Cytomegalovirus: implications for transplantation. Am J Transplant. 2016;16(8):2254–69.CrossRef Kaminski H, Fishman JA. The cell biology of Cytomegalovirus: implications for transplantation. Am J Transplant. 2016;16(8):2254–69.CrossRef
12.
Zurück zum Zitat Streblow DN, Orloff SL, Nelson JA. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol. 2007;19(5):577–82.CrossRef Streblow DN, Orloff SL, Nelson JA. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol. 2007;19(5):577–82.CrossRef
13.
Zurück zum Zitat Cannon RM, Ouseph R, Jones CM, Hughes MG, Eng M, Marvin MR. BK viral disease in renal transplantation. Curr Opin Organ Transplant. 2011;16(6):576–9.CrossRef Cannon RM, Ouseph R, Jones CM, Hughes MG, Eng M, Marvin MR. BK viral disease in renal transplantation. Curr Opin Organ Transplant. 2011;16(6):576–9.CrossRef
14.
Zurück zum Zitat Jackson JA, Kim EJ, Begley B, Cheeseman J, Harden T, Perez SD, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11(10):2228–34.CrossRef Jackson JA, Kim EJ, Begley B, Cheeseman J, Harden T, Perez SD, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11(10):2228–34.CrossRef
15.
Zurück zum Zitat Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of Cytomegalovirus infection and Disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87–91.CrossRef Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of Cytomegalovirus infection and Disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87–91.CrossRef
16.
Zurück zum Zitat Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013;61(5):649–72.CrossRef Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013;61(5):649–72.CrossRef
17.
Zurück zum Zitat Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001;286(19):2450–60.CrossRef Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001;286(19):2450–60.CrossRef
18.
Zurück zum Zitat Krajicek BJ, Limper AH, Thomas CF Jr. Advances in the biology, pathogenesis and identification of Pneumocystis pneumonia. Curr Opin Pulm Med. 2008;14(3):228–34.CrossRef Krajicek BJ, Limper AH, Thomas CF Jr. Advances in the biology, pathogenesis and identification of Pneumocystis pneumonia. Curr Opin Pulm Med. 2008;14(3):228–34.CrossRef
19.
Zurück zum Zitat Hoving JC, Kolls JK. New advances in understanding the host immune response to Pneumocystis. Curr Opin Microbiol. 2017;40:65–71.CrossRef Hoving JC, Kolls JK. New advances in understanding the host immune response to Pneumocystis. Curr Opin Microbiol. 2017;40:65–71.CrossRef
20.
Zurück zum Zitat Arend SM, Westendorp RG, Kroon FP, van't Wout JW, Vandenbroucke JP, van Es LA, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis. 1996;22(6):920–5.CrossRef Arend SM, Westendorp RG, Kroon FP, van't Wout JW, Vandenbroucke JP, van Es LA, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis. 1996;22(6):920–5.CrossRef
21.
Zurück zum Zitat Lee SH, Huh KH, Joo DJ, Kim MS, Kim SI, Lee J, et al. Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients. Sci Rep. 2017;7(1):1571.CrossRef Lee SH, Huh KH, Joo DJ, Kim MS, Kim SI, Lee J, et al. Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients. Sci Rep. 2017;7(1):1571.CrossRef
22.
Zurück zum Zitat de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13(6):559–69.CrossRef de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13(6):559–69.CrossRef
23.
Zurück zum Zitat Muhammad Iqbal AH, Lim SK, Ng KP, Tan LP, Chong YB, Keng TC. Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection. Transpl Infect Dis. 2012;14(4):E23–6.CrossRef Muhammad Iqbal AH, Lim SK, Ng KP, Tan LP, Chong YB, Keng TC. Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection. Transpl Infect Dis. 2012;14(4):E23–6.CrossRef
24.
Zurück zum Zitat Harari A, Zimmerli SC, Pantaleo G. Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol. 2004;65(5):500–6.CrossRef Harari A, Zimmerli SC, Pantaleo G. Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol. 2004;65(5):500–6.CrossRef
25.
Zurück zum Zitat Meijers RW, Litjens NH, Hesselink DA, Langerak AW, Baan CC, Betjes MG. Primary Cytomegalovirus infection significantly impacts circulating T cells in kidney transplant recipients. Am J Transplant. 2015;15(12):3143–56.CrossRef Meijers RW, Litjens NH, Hesselink DA, Langerak AW, Baan CC, Betjes MG. Primary Cytomegalovirus infection significantly impacts circulating T cells in kidney transplant recipients. Am J Transplant. 2015;15(12):3143–56.CrossRef
26.
Zurück zum Zitat Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010;5(1):43–65.CrossRef Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010;5(1):43–65.CrossRef
27.
Zurück zum Zitat Roths JB, Sidman CL. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J Clin Invest. 1992;90(2):673–8.CrossRef Roths JB, Sidman CL. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J Clin Invest. 1992;90(2):673–8.CrossRef
28.
Zurück zum Zitat Jankowska M, Cobo G, Lindholm B, Stenvinkel P. Inflammation and protein-energy wasting in the uremic milieu. Contrib Nephrol. 2017;191:58–71.CrossRef Jankowska M, Cobo G, Lindholm B, Stenvinkel P. Inflammation and protein-energy wasting in the uremic milieu. Contrib Nephrol. 2017;191:58–71.CrossRef
29.
Zurück zum Zitat Sardenberg C, Suassuna P, Andreoli MC, Watanabe R, Dalboni MA, Manfredi SR, et al. Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function. Nephrol Dial Transplant. 2006;21(1):160–5.CrossRef Sardenberg C, Suassuna P, Andreoli MC, Watanabe R, Dalboni MA, Manfredi SR, et al. Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function. Nephrol Dial Transplant. 2006;21(1):160–5.CrossRef
30.
Zurück zum Zitat Ahmed EB, Alegre ML, Chong AS. Role of bacterial infections in allograft rejection. Expert Rev Clin Immunol. 2008;4(2):281–93.CrossRef Ahmed EB, Alegre ML, Chong AS. Role of bacterial infections in allograft rejection. Expert Rev Clin Immunol. 2008;4(2):281–93.CrossRef
31.
Zurück zum Zitat Baron C, Forconi C, Lebranchu Y. Revisiting the effects of CMV on long-term transplant outcome. Curr Opin Organ Transplant. 2010;15(4):492–8.CrossRef Baron C, Forconi C, Lebranchu Y. Revisiting the effects of CMV on long-term transplant outcome. Curr Opin Organ Transplant. 2010;15(4):492–8.CrossRef
32.
Zurück zum Zitat Martin-Gandul C, Mueller NJ, Pascual M, Manuel O. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015;15(12):3024–40.CrossRef Martin-Gandul C, Mueller NJ, Pascual M, Manuel O. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015;15(12):3024–40.CrossRef
33.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1-155. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1-155.
Metadaten
Titel
Impact of Pneumocystis jirovecii pneumonia on kidney transplant outcome
verfasst von
Ji Eun Kim
Ahram Han
Hajeong Lee
Jongwon Ha
Yon Su Kim
Seung Seok Han
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Nephrology / Ausgabe 1/2019
Elektronische ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1407-x

Weitere Artikel der Ausgabe 1/2019

BMC Nephrology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.